CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the initiation of a Phase 2 clinical trial of retaspimycin hydrochloride (HCl), also known as IPI-504, the company's novel heat shock protein (Hsp90) inhibitor, in combination with docetaxel (also known as Taxotere®) in patients with non-small cell lung cancer (NSCLC). This study is supported by encouraging data from a Phase 1b trial in which retaspimycin HCl in combination with docetaxel was well-tolerated and showed clinical activity in NSCLC patients with poor prognoses, including patients with squamous cell carcinoma or with a history of heavy smoking. Full data from the Phase 1b trial will be presented during a poster session at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 4, 2011.
